• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Is Zoetis Inc. (NYSE: ZTS) Overvalued? Or Is It Worth Buying Now?

    1/7/25 4:15:00 PM ET
    $LKQ
    $ZTS
    Motor Vehicles
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LKQ alert in real time by email

    TROY, Mich., Jan. 7, 2025 /PRNewswire/ -- Zoetis's recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine considers Zoetis (NYSE:ZTS) as worthy of further study and has named Zoetis its "Stock to Study" for the March 2025 issue for investors' informational and educational use.

    The fundamental data is eye-opening; investors can view Zoetis's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors, at:  https://ssg.betterinvesting.org/trial/ssgplus/?ticker=ZTS.

    A full report on Zoetis will appear in the March 2025 issue of BetterInvesting Magazine. 

    The same issue of BetterInvesting Magazine will also include a fundamental review of LKQ Corp. (NASDAQ:LKQ) which the independent Editorial Advisory and Securities Review Committee believes is worthy of further study from an undervalued perspective. 

    Committee members are Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip Keating, CFA; Walter J. Kirchberger, CFA; Anne Nichols, CFA; and Dan Rutter, CFA.

    Securities mentioned are for study and presented for educational purposes only. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.

    About BetterInvesting:

    BetterInvesting™, a national 501(c)(3) nonprofit, investment education organization, has been empowering everyday Americans since 1951. Also known as the National Association of Investors™ (NAIC®), we have helped more than 5 million people from all walks of life learn how to improve their financial future. BetterInvesting provides unbiased, in-depth investing education and powerful online stock analysis tools to create successful lifelong investors. BetterInvesting staff, along with a dedicated community of volunteers across America, teach the organization's principles and time-tested methodology to individuals and investment clubs. For more information about BetterInvesting, please visit www.betterinvesting.org

    Follow us on LinkedIn, Instagram and Facebook.

    Contact: 877-275-6242

    Cision View original content:https://www.prnewswire.com/news-releases/is-zoetis-inc-nyse-zts-overvalued-or-is-it-worth-buying-now-302344973.html

    SOURCE National Association of Investors/BetterInvesting

    Get the next $LKQ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LKQ
    $ZTS

    CompanyDatePrice TargetRatingAnalyst
    Zoetis Inc.
    $ZTS
    1/22/2026$135.00Overweight → Neutral
    Piper Sandler
    Zoetis Inc.
    $ZTS
    12/15/2025$135.00Buy → Neutral
    BofA Securities
    LKQ Corporation
    $LKQ
    12/10/2025$39.00Overweight
    Stephens
    Zoetis Inc.
    $ZTS
    12/9/2025$136.00Equal Weight
    Barclays
    Zoetis Inc.
    $ZTS
    11/21/2025Sector Weight
    KeyBanc Capital Markets
    LKQ Corporation
    $LKQ
    11/12/2025$33.00Equal Weight
    Barclays
    Zoetis Inc.
    $ZTS
    7/17/2025$155.00Outperform → Market Perform
    Leerink Partners
    Zoetis Inc.
    $ZTS
    6/18/2025$160.00Buy → Hold
    Stifel
    More analyst ratings

    $LKQ
    $ZTS
    SEC Filings

    View All

    SEC Form 10-K filed by LKQ Corporation

    10-K - LKQ CORP (0001065696) (Filer)

    2/19/26 4:59:09 PM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary

    LKQ Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - LKQ CORP (0001065696) (Filer)

    2/19/26 7:33:45 AM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary

    SEC Form 144 filed by Zoetis Inc.

    144 - Zoetis Inc. (0001555280) (Subject)

    2/17/26 4:13:30 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LKQ
    $ZTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP - Policy & Administration Clark Michael S. covered exercise/tax liability with 601 shares and was granted 9,003 shares, increasing direct ownership by 8% to 112,575 units (SEC Form 4)

    4 - LKQ CORP (0001065696) (Issuer)

    2/23/26 6:00:21 PM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary

    SVP - Development & Strategy Hanley Walter P covered exercise/tax liability with 1,442 shares and was granted 21,606 shares, increasing direct ownership by 19% to 126,574 units (SEC Form 4)

    4 - LKQ CORP (0001065696) (Issuer)

    2/23/26 6:00:23 PM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary

    VP, Finance and Controller Cunningham Todd G was granted 5,252 shares and covered exercise/tax liability with 351 shares, increasing direct ownership by 28% to 22,669 units (SEC Form 4)

    4 - LKQ CORP (0001065696) (Issuer)

    2/23/26 6:00:20 PM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary

    $LKQ
    $ZTS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    January 13, 2022 - FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

    For Immediate Release: January 13, 2022 Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species.  Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type o

    1/13/22 10:26:13 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LKQ
    $ZTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zoetis to Acquire Animal Genomics Business from Neogen®, Accelerating Precision Animal Health Innovation

    Acquisition strengthens Zoetis' leadership in Precision Animal Health by integrating Neogen's global genomics capabilities, expanding predictive insights and individualized care worldwide Zoetis Inc. (NYSE:ZTS) the world's leading animal health company, today announced it has entered into a definitive agreement with Neogen Corporation (NASDAQ:NEOG) ("Neogen") to acquire Neogen's animal genomics business for $160 million, subject to customary closing adjustments. This acquisition aligns directly with Zoetis' strategy to drive future livestock innovation through genomics, reinforcing its commitment to livestock producers worldwide and advancing its Precision Animal Health portfolio. By inte

    3/2/26 7:00:00 AM ET
    $NEOG
    $ZTS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Zoetis to Participate in the Bank of America Securities 2026 Animal Health Summit

    Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Securities 2026 Animal Health Summit on Thursday, February 26, 2026 at 1:15 p.m. ET. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company. Interested parties can access the live audio webcast by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the world's leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent

    2/24/26 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LKQ Corporation Announces Results for Fourth Quarter and Full Year 2025

    Annual operating cash flow3 of $1.1 billion; free cash flow1,3 of $847 million Returned $116 million of Capital to Shareholders; $40 million of Share Repurchases and $76 million in Cash Dividends in the Fourth Quarter Board of Directors Initiated a Comprehensive Review of Strategic Alternatives to Enhance Shareholder Value 2026 Outlook Provided ANTIOCH, Tenn., Feb. 19, 2026 (GLOBE NEWSWIRE) -- LKQ Corporation (NASDAQ:LKQ) today reported fourth quarter and full year 2025 financial results and 2026 financial outlook. "Throughout 2025, our team relentlessly focused on what we could control, resulting in significant free cash flow generation despite sector headwinds across our g

    2/19/26 7:00:00 AM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary

    $LKQ
    $ZTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Urbain Xavier bought $481,756 worth of shares (15,000 units at $32.12), increasing direct ownership by 80% to 33,669 units (SEC Form 4)

    4 - LKQ CORP (0001065696) (Issuer)

    8/29/25 1:25:47 PM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary

    Director Clarke Andrew C bought $159,773 worth of shares (5,000 units at $31.95), increasing direct ownership by 31% to 21,172 units (SEC Form 4)

    4 - LKQ CORP (0001065696) (Issuer)

    8/27/25 3:51:39 PM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary

    President and CEO Jude Justin L bought $178,574 worth of shares (5,669 units at $31.50), increasing direct ownership by 2% to 286,446 units (SEC Form 4)

    4 - LKQ CORP (0001065696) (Issuer)

    8/27/25 3:51:23 PM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary

    $LKQ
    $ZTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zoetis downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Zoetis from Overweight to Neutral and set a new price target of $135.00

    1/22/26 8:26:41 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis downgraded by BofA Securities with a new price target

    BofA Securities downgraded Zoetis from Buy to Neutral and set a new price target of $135.00

    12/15/25 9:58:23 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stephens initiated coverage on LKQ with a new price target

    Stephens initiated coverage of LKQ with a rating of Overweight and set a new price target of $39.00

    12/10/25 8:28:13 AM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary

    $LKQ
    $ZTS
    Leadership Updates

    Live Leadership Updates

    View All

    CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025  S&P 500 Addition CRH CRH Mat

    12/5/25 5:49:00 PM ET
    $ASIX
    $BAH
    $BWA
    Major Chemicals
    Industrials
    Professional Services
    Consumer Discretionary

    Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026

    Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation Zoetis Inc. (NYSE:ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal decision to retire at the end of 2025. After a planful succession process, Zoetis has appointed Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic) to succeed Dr. Polzer in this role, effective January 1, 2026. Dr. Esch currently serves as Senior Vice President of Global Therapeutics at Zoetis and joined Zoe

    11/3/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Appoints Stephanie Tilenius to its Board of Directors

    Health entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as of December 1, 2025. Ms. Tilenius brings extensive experience in technology-forward, digital health organizations to the Zoetis Board. Ms. Tilenius is a serial entrepreneur and has founded several healthcare companies, including most recently a stealth company in the longevity AI space. Previously, she founded Vida Health, Inc., a leading B2B chronic care platform focusing on diabetes and obesity, and scaled it nationally for Fortune 500 companies, large payers and healthcar

    10/28/25 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LKQ
    $ZTS
    Financials

    Live finance-specific insights

    View All

    LKQ Corporation Announces Results for Fourth Quarter and Full Year 2025

    Annual operating cash flow3 of $1.1 billion; free cash flow1,3 of $847 million Returned $116 million of Capital to Shareholders; $40 million of Share Repurchases and $76 million in Cash Dividends in the Fourth Quarter Board of Directors Initiated a Comprehensive Review of Strategic Alternatives to Enhance Shareholder Value 2026 Outlook Provided ANTIOCH, Tenn., Feb. 19, 2026 (GLOBE NEWSWIRE) -- LKQ Corporation (NASDAQ:LKQ) today reported fourth quarter and full year 2025 financial results and 2026 financial outlook. "Throughout 2025, our team relentlessly focused on what we could control, resulting in significant free cash flow generation despite sector headwinds across our g

    2/19/26 7:00:00 AM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary

    Zoetis Reports Fourth Quarter and Full Year 2025 Results

    Reports Revenue of $2.4 Billion, Growing 3%, and Net Income of $603 Million, or $1.37 per Diluted Share, Increasing 4% and 6%, Respectively, on a Reported Basis for Fourth Quarter 2025 Delivers 4% Organic Operational Growth in Revenue and 4% Organic Operational Growth in Adjusted Net Income for Fourth Quarter 2025 Reports Adjusted Net Income of $648 Million, or Adjusted Diluted EPS of $1.48, for Fourth Quarter 2025 Reports Revenue of $9.5 Billion, Growing 2%, and Net Income of $2.7 Billion, or $6.02 per Diluted Share, Increasing 8% and 10%, Respectively, on a Reported Basis for Full Year 2025 Delivers 6% Organic Operational Growth in Revenue and 7% Organic Operational Growth i

    2/12/26 7:00:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Declares Second Quarter 2026 Dividend

    The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the second quarter of 2026. The dividend will be paid on Tuesday, June 2, 2026, to all holders of record of the Company's common stock as of the close of business on Monday, April 20, 2026. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide -- from veterinarians and pet owners to livestock producers. The com

    2/5/26 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LKQ
    $ZTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by LKQ Corporation

    SC 13G - LKQ CORP (0001065696) (Subject)

    11/7/24 4:30:56 PM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    2/13/24 5:17:36 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by LKQ Corporation (Amendment)

    SC 13G/A - LKQ CORP (0001065696) (Subject)

    2/13/24 5:08:05 PM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary